New Age Alpha Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

New Age Alpha Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.43M	Sell	10,927 -491	-4%	-$218K	0.23%	98
2026 Q1	$5.1M	Sell	11,418 -1,204	-10%	-$561K	0.24%	119
2025 Q4	$5.72M	Sell	12,622 -1,317	-9%	-$568K	0.25%	104
2025 Q3	$5.46M	Sell	13,939 -1,761	-11%	-$736K	0.23%	121
2025 Q2	$6.99M	Buy	15,700 +2,563	+20%	+$1.18M	0.31%	74
2025 Q1	$6.37M	Sell	13,137 -170	-1%	-$79.2K	0.29%	90
2024 Q4	$5.36M	Buy	+13,307	New	+$6.17M	0.22%	131

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

New Age Alpha Advisors's VRTX Position: Q2 2026 in Review

New Age Alpha Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 4.3% in Q2 2026, selling an estimated $218K and leaving 10,927 shares worth $5.43M. The position accounts for 0.23% of the portfolio, ranked #98.

New Age Alpha Advisors first reported a position in VRTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.99M in Q2 2025. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

New Age Alpha Advisors held 10,927 shares of Vertex Pharmaceuticals worth $5.43M as of Q2 2026.
New Age Alpha Advisors sold 491 Vertex Pharmaceuticals shares in Q2 2026, an estimated $218K.
Vertex Pharmaceuticals made up 0.23% of New Age Alpha Advisors's portfolio in Q2 2026, its #98 holding.
New Age Alpha Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
New Age Alpha Advisors's Vertex Pharmaceuticals position peaked at $6.99M in Q2 2025.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on New Age Alpha Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.